NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

NCT02761642

CompletedPhase 2

Sponsor: Hoffmann-La Roche

Conditions: Anemia

Interventions: Epoetin Beta

Countries: Italy

This study will evaluate the efficacy and safety of subcutaneous (SC) epoetin beta in anemic participants with breast cancer undergoing chemotherapy.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Adult female participants with histological diagnosis of breast cancer
* Any type of chemotherapy planned for greater than or equal to (\>/=) 9 weeks
* Hemoglobin level less than (\<) 11 grams per deciliter (g/dL)
* Participants able to receive iron supplement, if necessary

Exclusion Criteria:

* Known or suspected contraindications to epoetin beta
* Pregnancy or lactation period
* Diagnosis of anemia only due to iron-deficiency
* Diagnosis of thalasemic syndromes
* Epilepsy and/or cerebral metastasis
* Blood transfusion or treatment with any erythropoietic factor within 4 weeks before study start

Locations (27)

Arezzo, Italy
Ascoli Piceno, Italy
Bussolengo VR, Italy
Busto Arsizio, Italy
Casale Monferrato, Italy
Catania, Italy
Catanzaro, Italy
Chieti, Italy
Cuneo, Italy
Fano, Italy
Florence, Italy
Frosinone, Italy
Genova, Italy
Messina, Italy
Monza, Italy
Naples, Italy
Nocera Inferiore, Italy
Pavia, Italy
Pisa, Italy
Pordenone, Italy
Province of Macerata, Italy
Roma, Italy
Roma, Italy
Sassari, Italy
Torino, Italy
Vecchiazzano, Italy
Vittorio Veneto, Italy